慢性阻塞性肺病（COPD）市场:KOL的洞察

本报告提供全球慢性阻塞性肺病（COPD）市场相关调查，市场概要，以及已上市治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

治疗流程

调查目的

ICS/LABA/LAMA的3剂联合治疗

• 已上市治疗方法

生物学的疗法

• 抗IL5开发平台治疗
• 抗IL4/IL13开发平台治疗
• 抗TSLP开发平台治疗
• 抗IL33开发平台治疗

磷酸二酯[酉每]抑制剂

• 开发平台疗法

未来的治疗范例

• 主要的洞察摘要

附录

KOL快报

Explore the breakthrough potential of Dupixent for eosinophilic COPD, on the cusp of regulatory approval in the US and Europe, heralded by convincing Phase III results. Gain insights into the competitive landscape with updates on Nucala and Fasenra's clinical trials, highlighting the strategic positioning of biologics in COPD treatment. Stay informed on the latest advancements and prepare for the impact on COPD management.

Table of Contents

Executive summary (10)

Treatment algorithm

Research objectives (8)

ICS/LABA/LAMA triple combination therapies (10)

• Marketed therapies (10)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; GSK), Trimbow (beclometasone/formoterol/glycopyrronium; Chiesi), and Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate; AstraZeneca) (10)

Biological therapies (50)

• Anti-IL5 pipeline therapies (12)
  • Nucala (mepolizumab; GSK) and Fasenra (benralizumab; AstraZeneca) (12)
• Anti-IL4/IL13 pipeline therapies (8)
  • Dupixent (dupilumab; Regeneron/Sanofi) (8)
• Anti-TSLP pipeline therapies (7)
  • Tezspire (tezepelumab; Amgen/AstraZeneca) (7)
• Anti-IL33 pipeline therapies (23)
  • Itepekimab (REGN3500/SAR440340; Regeneron/Sanofi) (9)
  • Astegolimab (RG6149; Roche) (9)
  • Tozorakimab (MEDI3506; AstraZeneca) (5)

Phosphodiesterase inhibitors (24)

• Pipeline therapies (24)
  • Ensifentrine (RPL554; Verona) (13)
  • Tanimilast (CHF 6001; Chiesi) (11)

Future treatment paradigm (11)

• Key insights summary (11)

Appendix (5)

• KOL details (5)
  • KOLs from North America (1)
  • KOLs from the EU (3)

KOL Bulletins (2)